[ CAS No. 171361-65-2 ] {[proInfo.proName]}

Name: 171361-65-2|Ethyl 1-oxaspiro[2.5]octane-6-carboxylate|98+%
Brand: Ambeed
SKU: A684192
Rating: 95 (26 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 171361-65-2 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 171361-65-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 171361-65-2 ]

SDS Specification

Alternatived Products of [ 171361-65-2 ]

Product Details of [ 171361-65-2 ]

CAS No. :	171361-65-2	MDL No. :	MFCD12498695
Formula :	C₁₀H₁₆O₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GQJWTOYPOHWVKC-UHFFFAOYSA-N
M.W :	184.23	Pubchem ID :	45588272
Synonyms :

Safety of [ 171361-65-2 ]

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501	UN#:	2810
Hazard Statements:	H301-H311-H331	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 171361-65-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 171361-65-2 ]
Downstream synthetic route of [ 171361-65-2 ]

[ 171361-65-2 ] Synthesis Path-Upstream 1~4

1
[ 17159-79-4 ]
[ 1774-47-6 ]
[ 171361-65-2 ]

Yield	Reaction Conditions	Operation in experiment
65%	With potassium <i>tert</i>-butylate In dimethyl sulfoxide at 20℃;	Intermediate 9; Ethyl 1 -oxaspiror2.51octane-6-carboxylate; Procedure 9a; To a mixture of trimethylsulfoxonium iodide and potassium tert-butoxide (as reported in Synthetic Communications, 33(12), 2135-2143; 3.9 g, 11.76 mmol) was added a solution of ethyl 4-oxocyclohexanecarboxylate (1 g, 5.87 mmol, Aldrich) in DMSO (20ml). The mixture was left to stir overnight at room temperature. The mixture was poured into water and extracted with diethyl ether; the organic phase was dried on Na₂SO₄, filtered and evaporated in vacuo to afford the title compound (704.5 mg, 65percent), which was used without purification.Another batch of the same compound prepared using an analogous method showed the following NMR spectra:¹H NMR (400 MHz, CDCI3): δ 4.06 (2H, q), 2.49-2.59 (2H, m), 2.26-2.28 (1 H, m), 1.63- 2.04 (6H, m), 1.27-1.49 (2H, m), 1.20 (3H, t) cis/trans 65:35

Reference： [1] Patent: WO2008/92887, 2008, A1, . Location in patent: Page/Page column 28
[2] Patent: WO2008/129007, 2008, A1, . Location in patent: Page/Page column 32

2
[ 17159-79-4 ]
[ 18107-18-1 ]
[ 122898-08-2 ]
[ 171361-65-2 ]
[ 171361-62-9 ]

Reference： [1] Tetrahedron, 1995, vol. 51, # 37, p. 10259 - 10280
[2] Tetrahedron, 1995, vol. 51, # 37, p. 10259 - 10280
[3] Tetrahedron, 1995, vol. 51, # 37, p. 10259 - 10280

3
[ 17159-79-4 ]
[ 2181-42-2 ]
[ 171361-65-2 ]

Reference： [1] Patent: WO2008/92887, 2008, A1, . Location in patent: Page/Page column 28-29

4
[ 186581-53-3 ]
[ 17159-79-4 ]
[ 122898-08-2 ]
[ 171361-65-2 ]
[ 171361-62-9 ]

Reference： [1] Tetrahedron, 1995, vol. 51, # 37, p. 10259 - 10280
[2] Tetrahedron, 1995, vol. 51, # 37, p. 10259 - 10280

[ 171361-65-2 ] Synthesis Path-Downstream 1~88

1
[ 186581-53-3 ]
[ 17159-79-4 ]
[ 122898-08-2 ]
[ 171361-65-2 ]
[ 171361-62-9 ]
ethyl 4-oxocyclooctanecarboxylate [ No CAS ]

Reference： [1]Tetrahedron,1995,vol. 51,p. 10259 - 10280
[2]Tetrahedron,1995,vol. 51,p. 10259 - 10280

2
[ 17159-79-4 ]
[ 18107-18-1 ]
[ 122898-08-2 ]
[ 171361-65-2 ]
[ 171361-62-9 ]
ethyl 4-oxocyclooctanecarboxylate [ No CAS ]

Reference： [1]Tetrahedron,1995,vol. 51,p. 10259 - 10280
[2]Tetrahedron,1995,vol. 51,p. 10259 - 10280
[3]Tetrahedron,1995,vol. 51,p. 10259 - 10280

3
[ 22013-33-8 ]
[ 171361-65-2 ]
[ 1010814-77-3 ]

Yield	Reaction Conditions	Operation in experiment
94%	In ethanol; water;Heating / reflux;	A solution of l-oxa-spiro[2.5]octane-6-carboxylic acid ethyl ester obtained according to Tetrahedron, 1995, 51, 10259-80, (4.5 g, 24.4 mmol) and 2,3-dihydro-benzo[l,4]dioxin- 6-ylamine (3.7 g, 24.4 mmol) in EtOH/water (9:1, 100 ml) was heated at reflux overnight. The mixture was concentrated in vacuo and purified by chromatography (Hex:EA 2:1) to give the title amino alcohols (7.7 g, 94% yield) as an orange oil.1H NMR (DMSO d6) delta: 6.60-6.50 (m, IH); 6.20-6.10 (m, 2H); 5.90-5.70 (m, IH); 4.10-3.90 (m, 6H); 3.90-3.80 (m, 2H); 2.40-2.20 (m, IH); 1.80-1.40 (m, 7H), 1.40-1.20 (m, 2H); 1.10-1.00 (m, 4H).

Reference： [1]Patent: WO2008/26172,2008,A1 .Location in patent: Page/Page column 56

4
[ 62-53-3 ]
[ 171361-65-2 ]
[ 1044271-29-5 ]

Yield	Reaction Conditions	Operation in experiment
	In tert-butyl alcohol; at 150℃; for 1h;Microwave irradiation;	Intermediate 8; Ethyl 4-hvdroxy-4-r(phenylamino)methyllcvclohexanecarboxylate; Ethyl 1-oxaspiro[2.5]octane-6-carboxylate (Intermediate 9 procedure 9a, 704.5 mg, 3.82 mmol) was dissolved in t-BuOH (4ml) and aniline (697 mul, 7.65 mmol, Aldrich) was added. The reaction was stirred and heated at 1500C under microwave irradiation for two 30 minute cycles. The mixture was poured into a saturated aqueous solution of NH4CI and extracted with ethyl acetate; the organic phase was dried on Na2SO4, filtered and <n="29"/>evaporated in vacuo to give crude ethyl 4-hydroxy-4-[(phenylamino)methyl]- cyclohexanecarboxylate (1.19 g), which was used without further purification. Another batch of the same compound was prepared using an analogous method showed the following NMR spectra: 1H NMR (400 MHz, CDCI3): delta 7.14-7.24 (2H, m), 6.65-6.77 (3H, m), 4.10-4.20 (2H, m), 3.16-3.21 (1 H, m), 3.09-3.13 (1 H, m), 2.45-2.54 (1 H, m), 2.23-2.34 (1 H, m), 1.36-2.02 (9H, m), 1.22-1.30 (3H, m). cis/trans 65:35
	In tert-butyl alcohol; at 150℃; for 1h;Microwave irradiation;	Intermediate 7: Ethyl 4-hvdroxy-4-[(phenylamino)methyl1cvclohexanecarboxvlate; <n="33"/>Ethyl 1-oxaspiro[2.5]octane-6-carboxylate (Intermediate 8, 704.5 mg, 3.82 mmol) was dissolved in t-BuOH (4 ml) and aniline (697 mul, 7.65 mmol, commercially available from e.g. Aldrich) was added. The reaction was stirred and heated at 150 0C under microwave irradiation for two 30 minute cycles. The mixture was poured into a saturated aqueous solution of NH4CI and extracted with EtOAc; the organic phase was dried on Na2SC>4, filtered and evaporated in vacuo to give crude ethyl 4-hydroxy-4- [(phenylamino)methyl]cyclohexanecarboxylate (1.19 g), which was used without further purification. Another batch of the same compound prepared using an analogous method gave, 1 H-NMR (400 MHz, CDCI3): delta 1.22-1.30 (m, 3 H), 1.36-2.02 (m, 9 H), 2.23-2.34 (m, 1 H), 2.45-2.54 (m, 1 H), 3.09-3.13 (m, 1 H), 3.16-3.21 (m, 1 H), 4.10-4.20 (m, 2 H), 6.65- 6.77 (m, 3 H), 7.14-7.24 (m, 2 H).

Reference： [1]Patent: WO2008/92887,2008,A1 .Location in patent: Page/Page column 27-28
[2]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 6103 - 6107
[3]Patent: WO2008/129007,2008,A1 .Location in patent: Page/Page column 31-32

5
[ 17159-79-4 ]
[ 2181-42-2 ]
[ 171361-65-2 ]

Yield	Reaction Conditions	Operation in experiment
	With 2,8,9-tris(2-methylpropyl)-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane; In acetonitrile; at 0 - 20℃; for 1.5h;Product distribution / selectivity;	Procedure 9b; A mixture of 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane (1.14 ml, 3.94 mmol) and acetonitrile (15 ml) was added to a stirred suspension of trimethylsulphonium iodide (0.81 g, 3.97 mmol) and ethyl 4-oxocyclohexanecarboxylate (0.563 g, 3.31 mmol) at 0 0C. The mixture was stirred at 0 0C for 30 minutes then allowed to warm to room temperature and stirred for a further 1 hour. The reaction mixture was concentrated under reduced pressure then diluted with diethyl ether. The resulting suspension was stirred for 30 minutes then filtered and the filter cake was washed with more diethyl ether. The combined ethereal phases were concentrated under reduced pressure and the residue was chromatographed on SiO2 (Biotage 25M column) eluting with a gradient of 5%-15% EtOAc/cyclohexane to give a -60:40, trans:cis mixture of the title compound as a colourless oil (250 mg); <n="30"/>1 H NMR (400 MHz, CDCI3): delta 4.16 (2H both isomers, q), 2.65 (2H trans isomer, s), 2.62 (2H cis isomer, s), 2.35-2.48 (1 H both isomers, m), 1.68-2.14 (6H both isomers, m), 1.37- 1.52 (2H both isomers, m), 1.27 (3H both isomers, t).

Reference： [1]Patent: WO2008/92887,2008,A1 .Location in patent: Page/Page column 28-29

6
[ 17159-79-4 ]
[ 1774-47-6 ]
[ 171361-65-2 ]

Yield	Reaction Conditions	Operation in experiment
65%	With potassium tert-butylate; In dimethyl sulfoxide; at 20℃;Product distribution / selectivity;	Intermediate 9; Ethyl 1 -oxaspiror2.51octane-6-carboxylate; Procedure 9a; To a mixture of trimethylsulfoxonium iodide and potassium tert-butoxide (as reported in Synthetic Communications, 33(12), 2135-2143; 3.9 g, 11.76 mmol) was added a solution of ethyl 4-oxocyclohexanecarboxylate (1 g, 5.87 mmol, Aldrich) in DMSO (20ml). The mixture was left to stir overnight at room temperature. The mixture was poured into water and extracted with diethyl ether; the organic phase was dried on Na2SO4, filtered and evaporated in vacuo to afford the title compound (704.5 mg, 65%), which was used without purification.Another batch of the same compound prepared using an analogous method showed the following NMR spectra:1H NMR (400 MHz, CDCI3): delta 4.06 (2H, q), 2.49-2.59 (2H, m), 2.26-2.28 (1 H, m), 1.63- 2.04 (6H, m), 1.27-1.49 (2H, m), 1.20 (3H, t) cis/trans 65:35
	With potassium tert-butylate; In dimethyl sulfoxide; at 20℃;Product distribution / selectivity;	Intermediate delta: Ethyl 1-oxaspiror2.5loctane-6-carboxylate; To a mixture of trimethylsulfoxonium iodide and potassium tert-butoxide (as reported in Synthetic Communications, 33(12), 2135-2143; 3.9 g, 11.76 mmol) was added a solution of ethyl 4-oxocyclohexanecarboxylate (1 g, 5.87 mmole, Aldrich) in DMSO (20 ml). The mixture was left to stir overnight at room temperature. The mixture was poured into water and extracted with diethyl ether; the organic phase was dried on Na2SO4, filtered and evaporated in vacuo to afford ethyl 1-oxaspiro[2.5]octane-6-carboxylate (704.5 mg, 65%), which was used without purification. Another batch of the same compound prepared using an analogous method gave 1 H-NMR (400 MHz, CDCI3): delta 1.20 (t, 3 H), 1.27-1.49 (m, 2 H), 1.63-2.04 (m, 6 H), 2.26-2.28 (m, 1 H), 2.49-2.59 (m, 2 H), 4.06 (q, 2 H).

Reference： [1]Patent: WO2008/92887,2008,A1 .Location in patent: Page/Page column 28
[2]Patent: WO2008/129007,2008,A1 .Location in patent: Page/Page column 32

7
[ 51-79-6 ]
[ 171361-65-2 ]
(cis)-ethyl 2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]
(trans)-ethyl 2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium tert-butylate; In N,N-dimethyl-formamide; at 130℃; for 18h;	Intermediates 15 and 16; Ethyl trans-2-oxo-1-oxa-3-azaspiror4.5ldecane-8-carboxylate (Intermediate 15) and ethyl cis^-oxo-i-oxa-S-azaspiroK.deltaidecane-delta-carboxylate (Intermediate 16); <n="34"/>Potassium tert-butoxide (23.14 g, 206 mmol) was added portionwise to a stirred solution of ethyl carbamate (27.6 g, 309 mmol) in DMF (200ml) at room temperature. The resulting cloudy mixture was stirred for 1 hour then a solution of ethyl 1-oxaspiro[2.5]octane-6- carboxylate (prepared in an analogous manner to intermediate 9 procedure 9b) (19 g, 103 mmol) in DMF (50 ml) was added. The reaction mixture was heated to 13O0C overnight (-18 hours). Cool and dilute with saturated NaCI solution (20 ml) and extract with AcOEt (4 x 100 ml_). The combined organic layers were dried (Na2SO4), filtered and concentrated to a pale yellow oil. The residue was purified via Biotage (cyclohexane:AcOEt starting from 1 :1 to AcOEt pure; 65M column) to give Intermediate 15 (8.24g) and intermediate 16 (4.36g);Intermediate 151H-NMR (400 MHz, CDCI3): delta 5.39 (1 H, brs), 4.15 (2H, q), 3.37 (2H, s), 2.47 (1 H, sept),2.01-2.1 1 (2H, m), 1.80-1.95 (4H, m), 1.62-1.74 (2H, m), 1.27 (3H, t).Intermediate 16.1H-NMR (400 MHz, CDCI3): delta 5.27 (1 H, brs), 4.15 (2H, q), 3.32 (2H, s), 2.28-2.37 (1 H, m), 2.13 (2H, brd), 1.85-2.05 (4H, m), 1.53 (2H, td), 1.27 (3H, t).
		Intermediate 40: Ethyl 2-oxo-1-oxa-3-azaspiro[4.51decane-8-carboxylate; Ethyl carbamate (15.60 g, 175 mmol) was dissolved in DMPU (107 ml). After cooling to 0 0C potassium tert-butoxide (13.10 g, 1 17 mmol) was added in portions over 5 min. The cooling bath was removed and the reaction mixture was stirred for 1 hour at r.t.. Ethyl 1- oxaspiro[2.5]octane-6-carboxylate (Intermediate 8, prepared according to the third method above described, 10.75 g, 58.4 mmol) dissolved in DMPU (20 ml) was added and the mixture heated at 130 0C for 15 hours. The mixture was allowed to cool to r.t. and quenched with sat. aq. NH4CI (60 ml) while cooling by means of an ice-bath. The bath was removed and further sat. aq. NH4CI (300 ml) was added until a clear solution was obtained, which was diluted further with brine (300 ml). The aqueous solution was extracted with DCM (3x400 ml). The combined organics were dried (Na2SO4), filtered and the DCM evaporated under reduced pressure. The remaining DMPU was stripped off under reduced pressure (80 0C, 0.1 Torr) over 7 hours. The obtained solid was purified by silica gel chromatography eluting with DCMEtOAc: 8/2. 10 g of the title compound was collected (44.0 mmol, 75%) along with a second slightly impure batch of 2 g (8.36 mmol; 14.3%) of the title compound. 1 H-NMR (400 MHz, CDCI3): delta 5.07-5.22 (1 H, m), 4.15 (2H, q), 3.37 (0.6H, s), 3.32 (0.4H, s), 2.42-2.53 (0.4H, m), 2.26-2.39 (0.6H, m), 2.01-2.18 (2H, m), 1.79-2.01 (4H, m), 1.63-1.75 (0.6H, m), 1.46-1.58 (1.4H, m), 1.27 (3H, t) (6:4 mixture of cis and trans isomers).

Reference： [1]Patent: WO2008/92887,2008,A1 .Location in patent: Page/Page column 32-33
[2]Patent: WO2008/129007,2008,A1 .Location in patent: Page/Page column 47

8
[ 51-79-6 ]
[ 171361-65-2 ]
[ 1044269-93-3 ]
[ 1044269-95-5 ]

Yield	Reaction Conditions	Operation in experiment
		Potassium tert-butoxide (23.14 g, 206 mmol) was added portion-wise to a stirred solution of ethyl carbamate (27.6 g, 309 mmol) in DMF (200 ml) at room temperature. The resulting cloudy mixture was stirred for 1 hour then a solution of <strong>[171361-65-2]ethyl 1-oxaspiro[2.5]octane-6-carboxylate</strong> (Intermediate 1, 19 g, 103 mmol) in DMF (50 ml) was added. The reaction mixture was heated to 130 C. overnight (18 hours). The mixture was cooled and diluted with saturated NaCl solution (20 ml) and extracted with AcOEt (4×100 ml). The combined organic layers were dried (Na2SO4), filtered and concentrated to a pale yellow oil. The residue was purified via Biotage (cyclohexane: AcOEt starting from 1:1 to AcOEt pure; 65i column) to give Intermediate 2 (8.24 g) and intermediate 3 (4.36 g); Intermediate 21H NMR (400 MHz, CDCl3): delta 5.39 (1H, br s), 4.15 (2H, q), 3.37 (2H, s), 2.47 (1H, sept), 2.01-2.11 (2H, m), 1.80-1.95 (4H, m), 1.62-1.74 (2H, m), 1.27 (3H, t).Intermediate 3.1H NMR (400 MHz, CDCl3): delta 5.27 (1H, br s), 4.15 (2H, q), 3.32 (2H, s), 2.28-2.37 (1H, m), 2.13 (2H, br d), 1.85-2.05 (4H, m), 1.53 (2H, td), 1.27 (3H, t).
		In a 1 L four-necked round bottom flask, to an ice-bath cooled solution of ethyl carbamate (41.2 g, 462 mmol) in dry DMPU (190 ml) potassium tert-butoxide (34.6 g, 308 mmol) was added portion-wise over 15 mins. The cooling bath was removed and the mixture was stirred at r.t. for 45 min under nitrogen atmosphere. The solution became cloudy. Ethyl 1-oxaspiro[2.5]octane-6-carboxylate (prepared in a similar fashion to the preparation of Intermediate 1, 28.4 g, 154 mmol) was added by a syringe and the mixture was heated at 130 C. for 22 hours. The mixture was allowed to cool to r.t. and quenched at 0 C. with saturated aqueous NH4Cl (200 ml). The ice-bath was removed and further sat aq NH4Cl was added (1000 ml) followed by brine (600 ml) until clear solution. The aqueous solution was extracted with DCM (3×800 ml). The combined organic extracts were dried (Na2SO4), filtered and DCM evaporated under reduced pressure. The remaining DMPU was stripped off in speedvacuum system (80 C., 0.1 Torr) for 20 hours affording a yellowish solid as crude material (33 g). Purification by silica gel chromatography (75 L Biotage column) eluting with cyclohexaneEtOAcMeOH 6:3.5:0.5 afforded: ethyl (trans)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate (Intermediate 2, 13.7 g, 54.3 mmol) 1H NMR_(400 MHz, CDCl3): delta 1.28 (t, 3H), 1.70 (dd, 2H), 1.78-2.00 (m, 4H), 2.01-2.14 (m, 2H), 2.34-2.56 (m, 1H), 3.38 (s, 2H), 4.16 (q, 2H), 5.35 (br s, 1H); UPLCMS: 0.51 min, 228 [M+H]+ and 455 [2M+H]+.and ethyl (cis)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate (Intermediate 3, 15.g, 68.6 mmol) 1H NMR (400 MHz, CDCl3): delta 1.26 (t, 3H), 1.45-1.61 (m, 2H), 1.84-2.04 (m, 4H), 2.11 (d, 2H), 2.32 (s, 1H), 3.32 (s, 2H), 4.15 (q, 2H), 5.98 (br s, 1H); UPLCMS: 0.50 min, 455 [2M+H]+.

Reference： [1]Patent: US2009/203705,2009,A1 .Location in patent: Page/Page column 22-23
[2]Patent: US2009/203705,2009,A1 .Location in patent: Page/Page column 23
[3]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 6103 - 6107

9
[ 171361-65-2 ]
C₁₀H₁₈O₅ [ No CAS ]

Reference： [1]Synlett,2013,vol. 24,p. 502 - 506

10
[ 171361-65-2 ]
(1s,4s)-4-(ethoxycarbonyl)-1-fluorocyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: US2018/127368,2018,A1

11
[ 171361-65-2 ]
(1s,4s)-ethyl 4-fluoro-4-(hydroxymethyl)cyclohexane-1-carboxylate [ No CAS ]
(1r,4r)-ethyl 4-fluoro-4-(hydroxymethyl)cyclohexane-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
35%	With pyridine; hydrogen fluoride; In dichloromethane; at -78℃; for 4.5h;	(1 s,4s)-4-fluoro-4-(hydroxymethyl)cyclohexane-1-carboxylate Hydrogen fluoride (70% in pyridine; 5 mL, 5.43 mmol) was cooled to -78 C. in a polypropylene vial and treated with a solution of the mixture of ethyl (3r,6r)-1-oxaspiro[2.5]octane-6-carboxylate and ethyl (3s,6r)-1-oxaspiro[2.5]octane-6-carboxylate from Step A (1.0 g, 5.43 mmol) in DCM (5 mL). The mixture was stirred at -78 C. for 4.5 h, then was poured into ice-cold 2 M aqueous NH4OH (25 mL) and DCM (25 mL). The mixture was adjusted to pH 8 using concentrated aqueous NH4OH and extracted with DCM (2*50 mL). The combined organic phases were washed sequentially with 1 M aqueous HCl (50 mL) and brine (50 mL), dried and concentrated. The residue was purified by column chromatography on silica gel (24 g), eluting with EtOAc-hexanes (gradient from 0-30%), to give (1s,4s)-ethyl 4-fluoro-4-(hydroxymethyl)cyclohexanecarboxylate as a solid (390 mg, 35% yield). 1H NMR (400 MHz, CDCl3) delta 4.21-4.07 (m, 2H), 3.57 (dd, J=19.6, 5.7 Hz, 2H), 2.36-2.20 (m, 1H), 2.05 (dd, J=12.4, 9.4 Hz, 2H), 1.96-1.86 (m, 2H), 1.86-1.73 (m, 2H), 1.47-1.28 (m, 2H), 1.26 (t, J=7.2 Hz, 3H). (1s,4r)-ethyl 4-fluoro-4-(hydroxymethyl)cyclohexanecarboxylate was also isolated. 1H NMR (400 MHz, CDCl3) delta 4.14 (q, J=7.1 Hz, 2H), 3.72-3.55 (m, 2H), 2.62-2.46 (m, 1H), 1.99-1.87 (m, 2H), 1.85-1.72 (m, 6H), 1.26 (t, J=7.2 Hz, 3H).

Reference： [1]Patent: US2018/127368,2018,A1 .Location in patent: Paragraph 0453-0454

12
[ 22013-33-8 ]
[ 171361-65-2 ]
trans-3-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid ethyl ester [ No CAS ]

Reference： [1]Patent: WO2008/26172,2008,A1

13
[ 171361-65-2 ]
(trans)-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

14
[ 171361-65-2 ]
(cis)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

15
[ 171361-65-2 ]
(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

16
[ 171361-65-2 ]
(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]
(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

17
[ 171361-65-2 ]
ethyl (trans)-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]
ethyl (cis)-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

18
[ 171361-65-2 ]
ethyl (cis)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

19
[ 171361-65-2 ]
ethyl (trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

20
[ 171361-65-2 ]
ethyl (cis)-2-oxo-3-(3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

21
[ 171361-65-2 ]
ethyl (trans)-2-oxo-3-(3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

22
[ 171361-65-2 ]
(cis)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]
(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

23
[ 171361-65-2 ]
(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

24
[ 171361-65-2 ]
(trans)-8-(hydroxymethyl)-3-phenyl-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

25
[ 171361-65-2 ]
C₁₅H₁₆ClNO₃ [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

26
[ 171361-65-2 ]
ethyl (trans)-4-hydroxy-4-[(2-pyrimidinylamino)methyl]cyclohexanecarboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

27
[ 171361-65-2 ]
(trans)-2-oxo-3-(2-pyrimidinyl)-1-oxa-3-azaspiror4.5ldecane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

28
[ 171361-65-2 ]
[ 1073560-13-0 ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

29
[ 171361-65-2 ]
[ 1073560-12-9 ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

30
[ 171361-65-2 ]
ethyl (trans)-2-oxo-3-(2-pyrimidinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

31
[ 171361-65-2 ]
ethyl (cis)-3-(6-fluoro-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]
ethyl (trans)-3-(6-fluoro-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carbaldehyde [ No CAS ]
C₁₄H₁₇FN₂O₃ [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

32
[ 171361-65-2 ]
(trans)-3-(2-methyl-3-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

33
[ 171361-65-2 ]
(trans)-3-(6-methyl-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

34
[ 171361-65-2 ]
(trans)-3-(2-fluorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

35
[ 171361-65-2 ]
(trans)-3-(4-fluorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

36
[ 171361-65-2 ]
ethyl (trans)-3-(2-chlorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

37
[ 171361-65-2 ]
ethyl (cis)-2-oxo-3-(2-methyl-3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

38
[ 171361-65-2 ]
ethyl (trans)-3-(2-methyl-3-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

39
[ 171361-65-2 ]
ethyl (trans)-3-(2-fluorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

40
[ 171361-65-2 ]
ethyl (trans)-3-(6-methyl-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

41
[ 171361-65-2 ]
ethyl (cis)-3-(4-fluorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

42
[ 171361-65-2 ]
ethyl (trans)-3-(4-fluorophenyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

43
[ 171361-65-2 ]
ethyl (cis)-3-(6-fluoro-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

44
[ 171361-65-2 ]
ethyl (trans)-3-(6-fluoro-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

45
[ 171361-65-2 ]
cis-8-(2-chloro-1H-purin-8-yl)-3-phenyl-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

46
[ 171361-65-2 ]
2-[(trans)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]dec-8-yl]-1H-benzimidazole-5-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

47
[ 171361-65-2 ]
2-[(trans)-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]dec-8-yl]-3H-benzimidazole-5-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

48
[ 171361-65-2 ]
(trans)-N-(2-amino-4-cyanophenyl)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

49
[ 171361-65-2 ]
2-[(trans)-2-oxo-3-(4-fluorophenyl)-1-oxa-3-azaspiro[4.5]dec-8-yl]-1H-benzimidazole-5-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

50
[ 171361-65-2 ]
(trans)-N-(2-amino-5-cyanophenyl)-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

51
[ 171361-65-2 ]
(trans)-N-(2-amino-5-cyanophenyl)-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

52
[ 171361-65-2 ]
(trans)-3-(2-pyridinyl)-8-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

53
[ 171361-65-2 ]
(trans)-3-phenyl-8-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

54
[ 171361-65-2 ]
trans-3-(2-pyridinyl)-8-[6-(trifluoromethyl)-3H-imidazo[4.5-c]pyridin-2-yl]-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

55
[ 171361-65-2 ]
(trans)-3-(2-pyridinyl)-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

56
[ 171361-65-2 ]
(trans)-3-(2-pyridinyl)-8-[5-(3-pyridinyloxy)-1H-benzimidazol-2-yl]-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

57
[ 171361-65-2 ]
(trans)-3-(3-pyridinyl)-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

58
[ 171361-65-2 ]
(cis)-3-phenyl-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro-[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

59
[ 171361-65-2 ]
(trans)-3-phenyl-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro-[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1
[3]Patent: WO2008/129007,2008,A1

60
[ 171361-65-2 ]
(trans)-N-[2-amino-4-(trifluoromethyl)phenyl]-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

61
[ 171361-65-2 ]
(trans)-3-(2-pyrimidinyl)-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

62
[ 171361-65-2 ]
(trans)-N-[2-amino-4-(trifluoromethyl)phenyl]-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

63
[ 171361-65-2 ]
(trans)-N-(2-amino-5-cyanophenyl)-2-oxo-3-(4-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

64
[ 171361-65-2 ]
(trans)-N-(2-amino-4-cyanophenyl)-2-oxo-3-(4-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

65
[ 171361-65-2 ]
(trans)-N-[2-amino-5-(trifluoromethyl)phenyl]-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

66
[ 171361-65-2 ]
(trans)-N-[2-amino-5-(3-pyridinyloxy)phenyl]-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

67
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(2-pyrimidinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

68
[ 171361-65-2 ]
(trans)-3-(6-methyl-2-pyridinyl)-8-{5-[(trifluoromethyl)oxy]-3H-benzimidazol-2-yl}-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

69
[ 171361-65-2 ]
(trans)-N-[2-amino-4-(3-pyridinyloxy)phenyl]-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

70
[ 171361-65-2 ]
(trans)-N-[4-amino-6-(trifluoromethyl)-3-pyridinyl]-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

71
[ 171361-65-2 ]
(trans)-N-[5-amino-2-(trifluoromethyl)-4-pyridinyl]-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

72
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(2-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

73
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

74
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

75
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

76
[ 171361-65-2 ]
(trans)-3-(2-methyl-3-pyridinyl)-8-{5-[(trifluoromethyl)oxy]-3H-benzimidazol-2-yl}-1-oxa-3-azaspiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

77
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-phenyl-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1
[2]Patent: WO2008/129007,2008,A1

78
[ 171361-65-2 ]
(trans)-3-(4-fluorophenyl)-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro-[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

79
[ 171361-65-2 ]
(trans)-3-(2-fluorophenyl)-8-{5-[(trifluoromethyl)oxy]-1H-benzimidazol-2-yl}-1-oxa-3-azaspiro-[4.5]decan-2-one [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

80
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-3-(2-methyl-3-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

81
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-3-(6-methyl-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

82
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(2-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

83
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-3-(2-methyl-3-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

84
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(4-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

85
[ 171361-65-2 ]
(trans)-N-{2-amino-5-[(trifluoromethyl)oxy]phenyl}-3-(6-methyl-2-pyridinyl)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

86
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(4-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

87
[ 171361-65-2 ]
(trans)-N-{2-amino-4-[(trifluoromethyl)oxy]phenyl}-2-oxo-3-(2-fluorophenyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxamide [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

88
[ 171361-65-2 ]
lithium (trans)-2-oxo-3-(3-pyridinyl)-1-oxa-3-azaspiro[4.5]decane-8-carboxylate [ No CAS ]

Reference： [1]Patent: WO2008/129007,2008,A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 171361-65-2 ]

Esters

[ 15840-96-7 ]

Cyclohexyl cyclohexanecarboxylate

Similarity: 0.94

[ 77341-67-4 ]

4-(((1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl)oxy)-4-oxobutanoic acid

Similarity: 0.91

[ 3618-04-0 ]

trans-Ethyl 4-hydroxycyclohexanecarboxylate

Similarity: 0.91

[ 17159-80-7 ]

Ethyl 4-hydroxycyclohexanecarboxylate

Similarity: 0.91

[ 112245-04-2 ]

(R)-2-(2-(tert-Butoxy)-2-oxoethyl)-4-methylpentanoic acid

Similarity: 0.91

Related Parent Nucleus of
[ 171361-65-2 ]

Epoxides

[ 41088-52-2 ]

Methyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate

Similarity: 0.91

[ 3130-19-6 ]

Bis(7-oxabicyclo[4.1.0]heptan-3-ylmethyl) adipate

Similarity: 0.91

[ 64630-63-3 ]

7-Oxabicyclo[4.1.0]heptan-3-ylmethyl acrylate

Similarity: 0.71

[ 60456-26-0 ]

(R)-Oxiran-2-ylmethyl butyrate

Similarity: 0.67

[ 185-72-8 ]

1,6-Dioxaspiro[2.5]octane

Similarity: 0.60

Other Aliphatic Heterocycles

[ 41088-52-2 ]

Methyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate

Similarity: 0.91

[ 3130-19-6 ]

Bis(7-oxabicyclo[4.1.0]heptan-3-ylmethyl) adipate

Similarity: 0.91

[ 4430-31-3 ]

Octahydro-2H-chromen-2-one

Similarity: 0.88

[ 14166-28-0 ]

(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methanoisobenzofuran-1,3-dione

Similarity: 0.78

[ 335599-07-0 ]

Ethyl 3-oxa-bicyclo[3.1.0]hexane-6-carboxylate

Similarity: 0.75

Spiroes

[ 1489-97-0 ]

Ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate

Similarity: 0.74

[ 24730-88-9 ]

Ethyl 8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylate

Similarity: 0.72

[ 26845-47-6 ]

Methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate

Similarity: 0.71

[ 87787-08-4 ]

Methyl 8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylate

Similarity: 0.70

[ 1006686-08-3 ]

Ethyl 8-formyl-1,4-dioxaspiro[4.5]decane-8-carboxylate

Similarity: 0.69

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 171361-65-2 ] {[proInfo.proName]}

Quality Control of [ 171361-65-2 ]

Related Doc. of [ 171361-65-2 ]

Product Details of [ 171361-65-2 ]

Safety of [ 171361-65-2 ]

Application In Synthesis of [ 171361-65-2 ]

[ 171361-65-2 ] Synthesis Path-Upstream 1~4

[ 171361-65-2 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 171361-65-2 ]

Esters

Related Parent Nucleus of [ 171361-65-2 ]

Epoxides

Other Aliphatic Heterocycles

Spiroes

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 171361-65-2 ]

Related Parent Nucleus of
[ 171361-65-2 ]